Stockscreener 앱 받기
68.25
1.65%
-1.145
시간 외 거래:
68.25
Arcellx Inc 주식(ACLX)의 최신 뉴스
What analysts say about Arcellx Inc. stockTriple-digit profit margins - jammulinksnews.com
What drives Arcellx Inc. stock priceUnrivaled growth potential - jammulinksnews.com
Is Arcellx Inc. a good long term investmentFree Trading Strategy Suggestions - jammulinksnews.com
Bank of New York Mellon Corp Cuts Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Principal Financial Group Inc. Sells 184 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Xponance Inc. Acquires 190 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Price - 富途牛牛
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment - TipRanks
Teacher Retirement System of Texas Decreases Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) - Seeking Alpha
What makes Arcellx Inc. stock price move sharplyElite Stock Shortlist - Newser
Why Arcellx Inc. stock attracts strong analyst attentionFree High-Accuracy Stock Picks - Newser
GAMMA Investing LLC Buys 252 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Amalgamated Bank Buys 161 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Allspring Global Investments Holdings LLC Has $468,000 Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
How might ACLX's 2025 Q1 EPS forecast affect strategies? - AInvest
Piper Sandler maintains Overweight rating on Arcellx stock amid CAR-T safety study - Investing.com Nigeria
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers - Benzinga
(ACLX) Trading Signals - news.stocktradersdaily.com
Citi initiates Arcellx stock with buy rating on cell therapy potential - Investing.com
Citi initiates Arcellx stock with buy rating on cell therapy potential By Investing.com - Investing.com South Africa
Cancer Cell Market Exclusive Report with Detailed Study Analysis | Abbott Laboratories, Cellectis, Arcellx, GE - newstrail.com
Citigroup Initiates Arcellx at Buy With $110 Price Target - MarketScreener
Arcellx initiated with a Buy at Citi - TipRanks
Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus
Aileen Fernandes | People on The MoveSan Francisco Business Times - The Business Journals
Aileen Fernandes - The Business Journals
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment - TipRanks
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential - TipRanks
ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus
Arcellx stock maintains buy rating at H.C. Wainwright on launch plans - Investing.com
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating - TipRanks
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning - TipRanks
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy - TipRanks
0.51%
자본화:
|
볼륨(24시간):